-
公开(公告)号：US11591404B2
公开(公告)日：2023-02-28
申请号：US16884867
申请日：2020-05-27
发明人： Jennifer Brogdon , Saar Gill , David Jonathan Glass , Saad Kenderian , Andreas Loew , Joan Mannick , Michael C. Milone , Leon Murphy , David L. Porter , Marco Ruella , Yongqiang Wang , Qilong Wu , Jiquan Zhang
IPC分类号： C07K16/28 , C07K16/24 , C12N5/0783 , A61K39/00
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
-
2.发明申请公开(公告)号：US20220387486A1
公开(公告)日：2022-12-08
申请号：US17246351
申请日：2021-04-30
发明人： Barbara Brannetti , Jennifer Brogdon , Boris Engels , Brian Walter Granda , Lu Huang , Ming Lei , Na Li , Jimin Zhang , Carla Patricia Pinto Guimaraes , Saar Gill , Marco Ruella , Regina M. Young
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
-
公开(公告)号：US11413340B2
公开(公告)日：2022-08-16
申请号：US16065387
申请日：2016-12-21
申请人： Novartis AG , The Trustees of the University of Pennsylvania , DANA-FARBER CANCER INSTITUTE, INC. , PRESIDENT AND FELLOWS OF HARVARD COLLEGE
发明人： Jennifer Brogdon , Hwai Wen Chang , Boris Engels , Gordon James Freeman , Gerhard Johann Frey , Jennifer Marie Mataraza , Reshma Singh , Arlene Helen Sharpe
IPC分类号： A61K39/395 , A61K39/00 , A61P35/00 , A61K45/06
摘要： Provided are compositions for use in methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.
-
公开(公告)号：US11149076B2
公开(公告)日：2021-10-19
申请号：US16256731
申请日：2019-01-24
发明人： Hans Bitter , Jennifer Mary Bordeaux , Barbara Brannetti , Jennifer Brogdon , Naveen Kumar Dakappagari , Saar Gill , Steven Highfill , Lu Huang , Carl H. June , Ju Young Kim , Ming Lei , Na Li , Andreas Loew , Elena Orlando , Marco Ruella , Thai Tran , Jimin Zhang , Li Zhou
IPC分类号： C07K14/705 , C07K14/725 , C07K16/28 , A61K45/06 , A61K39/00 , A61K38/00
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.
-
公开(公告)号：US11028177B2
公开(公告)日：2021-06-08
申请号：US15400096
申请日：2017-01-06
发明人： Jennifer Brogdon , Saar Gill , Carl H. June , Michael D. Kalos , Andreas Loew , John Scholler
IPC分类号： C07K16/22 , C07K16/28 , C07K14/725 , C07K14/705 , A61K35/17 , A61K35/28 , A61K38/17 , A61K39/395 , A61K39/00
摘要： The invention provides compositions and methods for treating leukemia, for example, acute myeloid leukemia (AML) and B-cell acute lymphoid leukemia (B-ALL). The invention also relates to at least one chimeric antigen receptor (CAR) specific to CD123, vectors comprising the same, and recombinant T cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD123 binding domain. The invention also includes methods of bone marrow ablation for use in treatments necessitating bone marrow reconditioning or transplant.
-
6.发明授权公开(公告)号：US10525083B2
公开(公告)日：2020-01-07
申请号：US15727402
申请日：2017-10-06
发明人： Barbara Brannetti , Jennifer Brogdon , Boris Engels , Brian Granda , Lu Huang , Ming Lei , Na Li , Jimin Zhang , Carla Guimaraes
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
-
公开(公告)号：US20190330356A1
公开(公告)日：2019-10-31
申请号：US16382402
申请日：2019-04-12
申请人： Novartis AG , The Trustees of The University of Pennsylvania , UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
发明人： Jennifer Brogdon , Laura Alexandra Johnson , Carl H. June , Andreas Loew , Marcela Maus , John Scholler , Hideho Okada
摘要： The invention provides compositions and methods for treating diseases associated with expression of EGFRvIII. The invention also relates to chimeric antigen receptor (CAR) specific to EGFRvIII, vectors encoding the same, and recombinant T cells comprising the anti-EGFRvIII CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an anti-EGFRvIII binding domain.
-
公开(公告)号：US10357514B2
公开(公告)日：2019-07-23
申请号：US14680860
申请日：2015-04-07
发明人： Carl H. June , David L. Porter , Marcela Maus , Mariusz Wasik , Saar Gill , Joseph Fraietta , Marco Ruella , John Byrd , Jason Dubovsky , Amy Johnson , Natarajan Muthusamy , Saad Kenderian , Joan Mannick , David Glass , Leon Murphy , Jennifer Brogdon , William Raj Sellers
IPC分类号： A61K35/17 , A61K39/395 , A61K31/519 , A61K45/06 , C07K14/725 , A61K31/436 , A61K31/53 , C12N5/0783 , C07K16/28 , A61K39/00
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
-
9.再颁专利公开(公告)号：USRE49847E1
公开(公告)日：2024-02-27
申请号：US17569389
申请日：2022-01-05
发明人： Barbara Brannetti , Jennifer Brogdon , Boris Engels , Brian Granda , Lu Huang , Ming Lei , Na Li , Jimin Zhang , Carla Guimaraes , Saar Gill , Marco Ruella , Regina M. Young
CPC分类号： A61K35/17 , A61K38/1774 , A61P35/00 , C07K16/2803 , C07K16/2887 , C07K16/2896 , C12N15/85 , A61K2039/505 , C07K2317/24 , C07K2317/31 , C07K2317/622 , C07K2319/03 , C07K2319/33
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
-
公开(公告)号：US11865167B2
公开(公告)日：2024-01-09
申请号：US16382402
申请日：2019-04-12
申请人： Novartis AG , The Trustees of The University of Pennsylvania , UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
发明人： Jennifer Brogdon , Laura Alexandra Johnson , Carl H. June , Andreas Loew , Marcela Maus , John Scholler , Hideho Okada
CPC分类号： A61K39/001102 , A61K35/17 , A61K38/00 , C07K16/2863 , C07K16/3053 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/92 , C07K2319/00
摘要： The invention provides compositions and methods for treating diseases associated with expression of EGFRvIII. The invention also relates to chimeric antigen receptor (CAR) specific to EGFRvIII, vectors encoding the same, and recombinant T cells comprising the anti-EGFRvIII CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an anti-EGFRvIII binding domain.
-
-
-
-
-
-
-
-
-
搜索结果
59 条记录 (耗时 0.063 秒)
